A woman who used Wegovy and Ozempic says the drugmaker didn't adequately warn her, or other patients, of serious side effects ...

A woman who used the semaglutide drugs Wegovy and Ozempic to lose weight and treat diabetes says the drugmaker didn't ...

Interview with the Milanese immunologist Attilio Speciani. They call it an anti-obesity drug, but it's not just that: in ...

Analysts believe Hims & Hers will earn $0.57 per share this year and $0.80 next year. That prices the stock at 17 times next ...

A new study conducted by professional services firm Aon found employer health care expenditures are projected to surge 9% in 2025 to more than $16,000 per employee, markedly higher than the 6.5% ...

Businesses can take proactive steps now to best position themselves for a competitive advantage in the face of the seismic ...

Plus: GLP-1 drugs like Ozempic have potential to treat cancer, COVID-19, heart disease, and many other diseases.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 607.25% and ...

Eli Lilly sells a handful of different blockbuster drugs, but all attention right now is on its new ... Its biggest competitor is semaglutide, a drug Novo Nordisk (NYSE: NVO) markets as Ozempic and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Apart from her impressive career and talent, Vanessa Williams’ weight loss journey, too, has been quite inspiring for fans! Read about her diet, exercise, etc.

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.